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ABSTRACT 
Inflammatory choroidal neovascularization (iCNV) is an infrequent but an important cause of visual morbidity in patients 
with non-infectious uveitis and mostly occurs in intermediate or posterior uveitis. Punctate inner choroiditis, Vogt-
Koyanagi-Harada disease and multifocal choroiditis are among the leading causes of uveitis entities resulting in iCNVs. The 
diagnosis and management of iCNVs still remain a challenge. Use of multimodal imaging techniques such as fluorescein 
angiography, indocyanine green angiography, optical coherence tomography (OCT) and OCT-angiography may be 
necessary for the diagnosis of iCNVs. The treatment algorithm is not straightforward for iCNV. While control of the active 
inflammation with steroids and/or immunosuppressive agents is a key to success, various adjunctive treatment modalities 
such as thermal laser photocoagulation, photodynamic therapy and surgical membrane removal were also co-
administered previously. Nowadays, vascular endothelial growth factor (VEGF) inhibitors have become the most commonly 
administered adjunctive treatment option as they provide better anatomical and functional outcome and the recurrence 
rate of CNV is relatively low. We hereby reviewed important clinical studies and case series on anti-VEGF administration in 
iCNVs and briefly overviewed their results. 
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INTRODUCTION
Uveitis-related choroidal neovascularization (CNV) also 
termed as ''inflammatory CNV'' (iCNV) is a common 
cause of visual morbidity in uveitis, and the third leading 
cause of CNV following the exudative senile macular 
degeneration (SMD) and pathological myopia [1-3]. iCNV 
may develop during the course of  both infectious and 
non-infectious types of  uveitis [4, 5] and its incidence 
has been reported to be 2% in non-infectious posterior 
uveitis (NIPU) entities [5]. The incidence is especially 
relatively higher in some uveitis entities that affect or 
disrupt the Bruch’s membrane or neighboring layers. The 
highest risk of iCNV development in affected eyes has 
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been reported in punctate inner choroiditis (PIC), Vogt-
Koyanagi-Harada (VKH) disease and multifocal choroiditis 
(MFC) [5]. Its prevalence is reported to be 32-46% for 
MFC [6-9], 17-40% for PIC [4, 9, 10], 10-25% for 
serpiginous choroiditis (SC) [6, 11-16] and 9-15% for VKH 
disease [6, 17-19]. Besides common causes of iCNV 
aforementioned, CNVs can also be seen rarely in 
intermediate uveitis [20] or other NIPU entities including 
acute posterior multifocal placoid pigment 
epitheliopathy (APMPPE) [21], sympathetic ophthalmia 
(SO) [22], sarcoidosis [23], multiple evanescent white 
dots syndrome (MEWDS) [24] and birdshot 
retinochoroidopathy (BSCR) [25]. Though its exact 
pathogenesis remains unclear, the imbalance between 
stimulatory and inhibitory soluble mediators produced by 
the retinal pigment epithelium (RPE) seem to be the 
main triggering factor for its development [2]. Cytokines 
together with the vascular endothelial growth factor lead 
to impaired permeability and altered angiogenesis. 
Chronic inflammation induced Bruch's membrane-RPE 
complex disruption enables the neovascular buds 
originating from the choroid to pass through the 
disrupted layers into the sub-RPE or subretinal space. 
These immature vascular buds tend to thrive and 
subsequently leak and cause fluid leakage [6, 26, 27]. 
iCNV lesions often present with a new-onset 
metamorphopsia, vision loss and/or scotoma according 
to the location of  CNV. However, the lesion sometimes 
may be asymptomatic, especially if located extrafoveally 
and can only be noticed during a routine fundus 
examination or imaging [6]. iCNV is often typically a type 
2 CNV and can be peripapillar, extrafoveal, juxtafoveal or 
subfoveal. Rarely, iCNV presents as a type 1 CNV with or 
without a polypoidal component [6]. The active 
membrane is a grayish looking lesion and can have a 
hemorrhagic or exudative component. In the absence of 
significant exudation, sometimes the presence of a tiny 
intraretinal hemorrhage may indirectly point out to the 
membrane [4]. On the other hand, inactive or a healed 
membrane can be seen as a yellowish-white scar. As 
serous retinal detachment and intraretinal edema may 
also accompany an acute uveitis attack, the neovascular 
membrane may be easily overlooked and the clinical 
picture can be interpreted as the presentation of an 
uveitis attack [6]. Color fundus picture, fluorescein 
angiographic (FA), indocyanine green angiographic (ICGA) 
and optical coherence tomographic (OCT) images of a 
case with unilateral MFC together with  a type 1 CNV and 
a polyp at the peripapillary area are shown in Figure 1.
 
Figure 1. Images of a 64-year-old man with peripapillary healed multifocal choroiditis (MFC) scars and inflammatory choroidal neovascularization 
(iCNV). Right eye, color fundus picture showing peripapillary hard exudates and dot hemorrhages (A). Early venous phase of fluorescein angiogram 
showing a hypofluorescent lesion complex at the peripapillary area and multiple subtle hypofluorescent scattered dots (B) Late venous phase of 
fluorescein angiogram with profuse peripapillary hyperfluorescence (C), Early indocyanine green angiogram revealing peripapillary hypocyanesence of 
the lesion complex (D) and later frames showing peripapillary hypercyanesent lesion with a faintly seen dark halo suggestive of a ''polyp''  (yellow 
arrow) together with  peripapillary hypocyanescent dots representing the old scars (E). Optical coherence tomography (OCT) showing subretinal fluid 
with sharp pigment epithelial detachment corresponding to the polyp (F). One month following thermal laser photocoagulation and anti-VEGF 
treatment, color fundus picture (G) and OCT (H) show some clinical improvement.  
 
 
 
  
Med Hypothesis Discov Innov Ophthalmol. 2020; 9(2)  
120 INFLAMMATORY CHOROIDAL NEOVASCULAR MEMBRANES IN NONINFECTIOUS UVEITIS 
 
Figure 2.  A 74-year-old male with bilateral old serpiginous like choroiditis scars and left active inflammatory choroidal neovascularization (iCNV) and a 
right disciform scar. Color fundus picture of the right (A) and left eyes (B) showing widespread healed choroiditis areas together with the scattered 
pigmentary changes. The right eye had a macular fibrotic scar (black arrow) and the left eye had a small grayish membrane (red arrow) with retinal 
hemorrhage. Late-phase fluorescein angiogram of the right (C) and left eyes (D) shows fluorescein blockage resulting from the widespread chorioretinal 
atrophic areas and pigment clumping. There was a hyperfluorescent foveal lesion with diffuse leakage (green arrow) corresponding to iCNV and a 
hypofluorescent area corresponding to hemorrhage (yellow arrow). OCT section shows a hyperreflective foveal scar in the right eye (E) and fluid 
accumulation with hyperreflective material in the subretinal space in the left eye (F). He was treated with four ranibizumab injections within one year. 
The iCNV healed with a scar formation and few residual persistent intraretinal cysts (G, H). 
 
FA, ICGA and OCT are among the conventional imaging 
methods for determining the presence and location of 
CNV in eyes with uveitis [28]. Since iCNV is often a classic 
type of membrane, it can be visualized by FA [29-31]. 
However, ICGA may also be used if the lesion is an occult 
lesion as ICGA visualize the occult lesions much better 
than FA. As the iCNV also causes early iso- or hyper-
fluorescence with late dye leakage [32], the presence of 
iCNV may be misrecognized as an active inflammatory 
lesion. On the other hand, OCT delineates the activity of 
iCNV by detecting the membrane itself and also 
accompanying intraretinal and/or subretinal fluid 
accumulation at the lesion area. Multimodal imaging of a 
74-year-old male with a type 2 CNV associated with 
inactive bilateral serpiginous like choroiditis is 
demonstrated in Figure 2.  
Nowadays, OCT-Angiography (OCTA) is preferred for 
detection of CNV since vascular networks can be 
depicted many times by OCTA [33, 34] CNV is classified 
into three groups based on its visualization in OCTA; 
group A (well-circumscribed vascular complex), group B 
(moderately circumscribed vascular complex) and group 
C (poorly circumscribed vascular complex) [35]. 
Although various treatment modalities including 
vitreoretinal surgery, laser photocoagulation, 
corticosteroids (local and/or systemic), systemic 
immunosuppressive treatment and photodynamic 
therapy (PDT) have been used, VEGF inhibitors seem to 
become an important tool in the management of iCNV 
[2, 4, 6] and can be used alone or in conjunction with 
above-mentioned therapies. Also, there is an anectodal 
use of systemic sirolimus and intravitreal methotrexate 
injection [36, 37]. All therapeutic interventions 
essentially target neo-angiogenic and/or inflammatory 
mechanisms underlying iCNV development. Since even 
subclinical inflammation can provide a favorable 
environment for iCNV formation, suppression of any 
active inflammation is mandatory. Local and/or systemic 
steroids are used effectively alone or mostly in 
combination with immunosuppressive agents 
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(cyclosporin, methotrexate and mycophenolate mofetil) 
and/or biologics (such as infliximab, adalimumab, etc.) to 
control the intraocular inflammation [4, 6, 38, 39]. 
Steroids can also be used either alone or combined with 
Photodynamic therapy (PDT) and/or anti-VEGF therapy. 
PDT has been used to treat subfoveal and/or juxtafoveal 
iCNV for various types of uveitis including MFC [40], PIC 
[41] and VKH [42] when there is no response with other 
treatment modalities prior to antiVEGF era. Subsequent 
subretinal fibrosis, atrophy and recurrence of iCNV 
restricted the use of PDT [28, 43]. Thermal laser 
photocoagulation can be an option for the treatment of 
extrafoveal iCNV in some selected cases[2]. This mini-
review briefly summarizes the place of intravitreal anti-
VEGF therapy in patients with non-infectious uveitis and 
iCNV. 
METHODS  
An extensive literature search was performed in PubMed 
between 1979 and 2020 with the extracted keywords of 
‘’inflammatory choroidal neovascularization'', 
''intravitreal anti-VEGF therapy'', and ''non-infectious 
uveitis'') to retrieve suitable studies on intravitreal 
treatment in patients with iCNV associated with NIU. 
Studies regarding NIU-related iCNV and studies with 
sample size ≥ 5 eyes were evaluated. 
 
Intravitreal Anti-VEGF Therapy and Clinical Studies  
Bevacizumab (Avastin; Genentech Inc.), Ranibizumab 
(Lucentis; Genentech Inc., South San Francisco, 
California, The USA) and Aflibercept (Eylea; Regeneron 
Pharmaceutical Inc., Tarrytown, NY, The USA and Bayer 
Healthcare, Berlin, Germany) have been used 
successfully for treating many retinal diseases 
characterized by increased vascular permeability and/or 
neo-angiogenesis, such as  exudative age-related macular 
degeneration (AMD), myopic CNV, macular edema 
secondary to retinal vein occlusion or diabetic 
retinopathy (DR), and proliferative DR [44]. Nowadays, 
anti-VEGF agents become an important therapeutic tool 
in patients with iCNV and are used alone or in 
combination with the above-mentioned treatment 
modalities. Table 1 summarizes the studies regarding the 
administration of anti-VEGF agents in the management 
of iCNV associated with NIPU [45-51]. 
Anti-VEGF therapy has gained popularity as promising 
outcomes have been reported in many studies 
conducted with bevacizumab, ranibizumab or aflibercept 
[3, 6, 45-52]. However, most of the studies were 
uncontrolled-retrospective studies involving small 
sample size or case series. Currently, there is still no well-
accepted anti-VEGF treatment algorithm for iCNVs. In a 
very recent clinical trial conducted by Invernizzi et al. [3], 
the data of 24-month outcomes of anti-VEGF injections in 
82 eyes with iCNV caused by infectious and non-
infectious etiologies were retrospectively analyzed. Most 
patients had a non-infectious etiology [PIC/MFC (40 
eyes), VKH (9 eyes), sarcoidosis (4 eyes) and intermediate 
uveitis (3 eyes)]. Patients were divided into 2 groups 
according to the treatment regimen: LOADING group 
(eyes treated with 3 anti-VEGF injections monthly then 
pro re nata (PRN) and PRN group (eyes treated with anti-
VEGF injections PRN from the beginning). Patients 
received either anti-VEGF agents as monotherapy 
[bevacizumab (61 eyes), ranibizumab (3 eyes) and 
aflibercept (5 eyes)] or switch (any combination of anti-
VEGF) therapy (13 eyes). The authors reported that visual 
acuity improved significantly in both groups during the 
study period compared to its baseline. However, there 
was a significantly higher mean number of injections in 
the LOADING group (4.5) than in the PRN group (2.5), but 
the CNV recurrence rate was the same. The authors 
emphasized success of anti-VEGF therapy in the 
treatment of iCNV and concluded that PRN regimen had 
similar efficacy with the LOADING regimen. Parallel 
results were reported in the MINERVA study investigating 
the efficacy and safety of ranibizumab in uncommon 
causes of CNVs and better visual outcomes were 
reported at month 2 with ranibizumab therapy compared 
to the sham group. Furthermore, improvement in visual 
acuity maintained until month 12. The MINERVA study 
group suggested that individualized PRN regimen was 
effective in achieving visual acuity gains, regardless of 
baseline visual acuity and underlying CNV etiology [53]. 
In addition to ideal protocol selection, switch therapy 
among anti-VEGF agents and recurrence rate are still 
not well-determined in cases with iCNV. The recurrence 
rate of iCNV has been reported between 0 and 50% in 
various studies [54-56]. Several studies have reported 
less mean or median number of injections (ranged; 1.5 
to 3.5) in NIPU-related iCNV compared to patients with 
exudative AMD [45-51]. Also, several multicenter 
prospective studies on anti-VEGF therapy for exudative 
AMD have disclosed that AMD eyes often needed VEGF 
inhibitors for a very long time. Though the need for 
prolonged anti-VEGF injections seems to be less 
necessary in eyes with iCNV the ideal injection number 
remains still obscure in iCNV due to lack of long-term 
reports [6]. In a case series on anti-VEGF switch 
therapy, the authors found that sufficient response 
might not be obtained after switching to aflibercept 
from ranibizumab in patients with MFC and unresolving 
intraretinal fluid [57]. 
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Table 1. The Summary of Studies on Inflammatory Choroidal Neovascularization Treatment with Intravitreal Vascular Endothelial Growth Factor  
Inhibitors in Non-infectious Uveitis. 
 
Abbreviations: VEGF: vascular endothelial growth factor; BVCA: best-corrected visual acuity; VKH: Vogt–Koyanagi–Harada; PIC: punctate inner 
choroidopathy; MFC: multifocal choroiditis; BSCR: birdshot chorioretinopathy; MFCPU: multifocal choroiditis and panuveitis; SO: sympathetic 
ophthalmia; SC: serpiginous choroiditis; NR: not reported; CFT: central foveal thickness; logMAR: logarithm of minimum angle of resolution; n: number. 
Study design, sample size and 
follow-up  
Type of uveitis 
(Number of eyes) 
Anti-VEGF therapy  
(Mean or median number of 
injections)  
Neovascular membrane 
localization 
Anatomical and/or functional 
outcomes,  adverse event and 
recurrence 
Barth et al. [45], (2018) 
*Retrospective 
*16 patients 
*15 months (6-40) 
PIC (16) *Bevacizumab (n:13) 
   Ranibizumab (n:2) 
   Both (n:1) 
 
*3.5 (1-9) 
8 subfoveal 
7 juxtafoveal 
1 extrafoveal 
*BCVA improved in eight eyes, 
remained stable in four eyes and 
decreased in four eyes. BCVA 
improved from logMAR 0.36 to 
logMAR 0.32 
*CFT decreased from 344 µm to 276 
µm 
*Recurrence: 8 eyes (50%) 
Fine et al.[46], (2009) 
*Retrospective 
*5 patients (6 eyes) 
* 41.5 weeks (25–69) 
 
MFC (6) *Bevacizumab (n: 5 eyes) 
   Ranibizumab (n: 0) 
   Both (n: 1 eye) 
*2.3 (1– 6). 
NR *Five of six eyes improved to 20/30 
acuity or better at 6 months. 
*One eye decreased to 20/400 due 
to bevacizumab-associated RPE tear 
Doctor et al.[47], (2009) 
*Retrospective 
*5 patients (6 eyes) 
*15.3 months 
 
 
BSCR (1) 
VKH (1) 
MFCPU (1) 
SO (1) 
Idiopathic  (2) 
*Bevacizumab (n: 6 eyes) 
 
*2.7 (1-5) 
5 subfoveal 
1 juxtafoveal 
 
*BCVA improved in 60% of patients 
at the last follow-up. 
*No adverse event 
Cornish et al.[48], (2011) 
*Retrospective 
*9 patients (9 eyes) 
*14.9 months (11-25) 
PIC (9 eyes) *Bevacizumab (n: 6 eyes) 
   Ranibizumab (n: 3 eyes) 
*2.9 (1-6) 
NR *BCVA improved from logMAR 0.38 
to logMAR 0.12 
*No adverse event 
Parodi et al.[49], (2014) 
*Prospective 
*7 patients (7 eyes) 
*12 months 
SC (7 eyes) *Bevacizumab (n: 7 eyes) 
*1.5 (1-5) 
 
1 subfoveal 
6 juxtafoveal 
 
*BVCA improved in 2 eyes, 
remained stable in 4 eyes and 
decreased in one eye. 
Mean BCVA: 0.50 logMAR at 
baseline and 0.48 logMAR at last 
visit. 
*Mean CFT decreased from 254 µm 
to 196 µm at the last visit. 
* No adverse event 
Menezo et al.[50], (2010) 
*Retrospective 
*10 patients (10 eyes) 
*12.5 months (6-34) 
 
PIC (10 eyes) *Ranibizumab (n: 9 eyes) 
  Bevacizumab (n: 0) 
  Both (1 eye)  
 
*1.9 (1-5) 
NR *Nine eyes remained stable or 
improved their vision and one eye 
deteriorated. 
*Mean CFT decreased from 302 µm 
to 283 µm after anti-VEGF therapy 
* No adverse event 
Tran et al.[51], (2008) 
*Retrospective 
*10 patients (10 eyes) 
*7.5 months  
 
MFC (6 eyes) 
SO (2 eyes) 
SC (1 eye) 
VKH (1 eye) 
*Bevacizumab (10 eyes) 
 
*2.5 (1-4) 
8 subfoveal 
2 juxtafoveal 
 
*BVCA improved from logMAR 0.62 
to logMAR 0.45 at last visit 
*CFT decreased from 326 µm to 267 
µm at last visit 
* No adverse event 
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Figure 3. A 17-year-old girl with bilateral intermediate uveitis and right inflammatory choroidal neovascularization (iCNV). Color fundus picture (A) 
showing a subfoveal yellow-orange-colored lesion corresponding to pigment epithelial detachment (black arrow). Fundus angiogram (B, C) revealing ill-
defined iCNV, disc staining and peripheral vascular leakage (black arrows). Optical coherence tomography angiography image of the superficial slab 
showing normal appearance (D), but deep (E), outer retina (F) and choriocapillaris (G) slabs revealing poorly circumscribed vascular complex with 
motion artifacts (yellow arrows). Optical coherence tomography (OCT) image (H) illustrating CNV and pigment epithelial detachment with pitchfork sign 
(red arrow). Four weeks after intravitreal injection of ranibizumab, color fundus photograph (I) and OCT image (J) showing partial regression of iCNV 
and resolution of subretinal fluid (red arrows). 
 
 
Although iCNV is commonly associated with posterior 
uveitis, it can be rarely seen in intermediate uveitis 
(0.06%). The membrane is often located at the 
peripapillary area. The outcome of anti-VEGF treatment in 
this group is not well-known. However, the case series 
reported that iCNV in intermediate uveitis appears to 
respond well to anti-VEGF therapy [20, 58]. Unilateral 
iCNV and response to single intravitreal ranibizumab 
administration together with systemic steroid and 
azathioprine in a young girl with bilateral intermediate 
uveitis is illustrated in Figure 3. 
Some clinicians may prefer a combination therapy of 
intravitreal VEGF inhibitors and oral or intravitreal steroids 
to avoid recurrence of iCNV and suppress the concomitant 
inflammation. In a retrospective study conducted by Wu 
et al.[59], twenty-four eyes of 22 patients with PIC and 
iCNV were treated with either intravitreal ranibizumab 
monotherapy (14 eyes) or combined oral corticosteroid 
and intravitreal ranibizumab therapy. Although visual 
improvement was achieved in both treatment groups, the 
authors reported that less development of new PIC lesion 
and CNV recurrence were observed in the combination 
group. Intravitreal steroids including triamcinolone 
acetonide (TA) and dexamethasone implant (IDI) have also 
been administered to obtain rapid remission avoiding 
possible systemic side effects of systemic steroid and/or 
immunosuppressive agents. Unfortunately, there are no 
randomized controlled trials about the efficacy of 
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intravitreal steroids in NIU-related iCNVs. Pai et al. [60] 
reported that the combination of intravitreal TA and 
bevacizumab was an effective and reliable treatment 
alternative in VKH related recurrent iCNVs. Saatci et al. 
[16] administered a single simultaneous intravitreal 
dexamethasone implant (IDI) and ranibizumab injection in 
a case with active SC and iCNV and reported a favorable 
anatomic and functional outcome. Tsaousis et al. [61] 
obtained encouraging results and long-term stability with 
the use of IDI in patients with PIC-related iCNV. 
CONCLUSION 
Various treatment options are implemented for the 
management of i-CNV associated with non-infectious type 
of uveitis. It is crucial to remember that underlying active 
or subclinical inflammation should be held under control 
as much as possible with steroids and/or 
immunosuppressive treatments or biologics where 
appropriate. However, locally targeted therapy is often 
given to obtain visually and anatomically satisfactory 
outcomes in many cases. Administration of anti-VEGF 
agents seems to be quite useful and characterized with a 
relatively low iCNV recurrence rate. However, randomized 
controlled trials with a larger sample size may be useful to 
search the optimal anti-VEGF treatment regimen and the 
superior anti-VEGF agent. 
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